nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Infusion site reaction—Docetaxel—head and neck cancer	0.0921	0.101	CcSEcCtD
Conivaptan—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.0432	0.0476	CcSEcCtD
Conivaptan—Phlebitis—Vinblastine—head and neck cancer	0.0253	0.0279	CcSEcCtD
Conivaptan—Oral candidiasis—Docetaxel—head and neck cancer	0.0224	0.0247	CcSEcCtD
Conivaptan—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.0211	0.0232	CcSEcCtD
Conivaptan—Laryngeal pain—Docetaxel—head and neck cancer	0.0209	0.023	CcSEcCtD
Conivaptan—Sepsis—Fluorouracil—head and neck cancer	0.0171	0.0189	CcSEcCtD
Conivaptan—Infestation NOS—Hydroxyurea—head and neck cancer	0.0153	0.0169	CcSEcCtD
Conivaptan—Infestation—Hydroxyurea—head and neck cancer	0.0153	0.0169	CcSEcCtD
Conivaptan—Cardiac failure—Fluorouracil—head and neck cancer	0.0147	0.0162	CcSEcCtD
Conivaptan—Candida infection—Docetaxel—head and neck cancer	0.0136	0.015	CcSEcCtD
Conivaptan—Angiopathy—Hydroxyurea—head and neck cancer	0.0125	0.0138	CcSEcCtD
Conivaptan—Sepsis—Docetaxel—head and neck cancer	0.0124	0.0136	CcSEcCtD
Conivaptan—Anaemia—Vinblastine—head and neck cancer	0.0122	0.0134	CcSEcCtD
Conivaptan—Phlebitis—Docetaxel—head and neck cancer	0.012	0.0132	CcSEcCtD
Conivaptan—Erythema—Hydroxyurea—head and neck cancer	0.012	0.0132	CcSEcCtD
Conivaptan—Hypertension—Vinblastine—head and neck cancer	0.0114	0.0125	CcSEcCtD
Conivaptan—Pneumonia—Fluorouracil—head and neck cancer	0.0111	0.0122	CcSEcCtD
Conivaptan—Anaemia—Hydroxyurea—head and neck cancer	0.0111	0.0122	CcSEcCtD
Conivaptan—Infestation NOS—Fluorouracil—head and neck cancer	0.011	0.0122	CcSEcCtD
Conivaptan—Infestation—Fluorouracil—head and neck cancer	0.011	0.0122	CcSEcCtD
Conivaptan—Atrial fibrillation—Docetaxel—head and neck cancer	0.0109	0.012	CcSEcCtD
Conivaptan—Urinary tract infection—Fluorouracil—head and neck cancer	0.0107	0.0118	CcSEcCtD
Conivaptan—Cardiac failure—Docetaxel—head and neck cancer	0.0106	0.0117	CcSEcCtD
Conivaptan—Hyponatraemia—Docetaxel—head and neck cancer	0.0104	0.0114	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.0101	0.0112	CcSEcCtD
Conivaptan—Infection—Hydroxyurea—head and neck cancer	0.00972	0.0107	CcSEcCtD
Conivaptan—Dehydration—Docetaxel—head and neck cancer	0.00962	0.0106	CcSEcCtD
Conivaptan—Nervous system disorder—Hydroxyurea—head and neck cancer	0.0096	0.0106	CcSEcCtD
Conivaptan—Skin disorder—Hydroxyurea—head and neck cancer	0.00951	0.0105	CcSEcCtD
Conivaptan—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00945	0.0104	CcSEcCtD
Conivaptan—Pain—Vinblastine—head and neck cancer	0.00918	0.0101	CcSEcCtD
Conivaptan—Constipation—Vinblastine—head and neck cancer	0.00918	0.0101	CcSEcCtD
Conivaptan—Feeling abnormal—Vinblastine—head and neck cancer	0.00885	0.00974	CcSEcCtD
Conivaptan—Erythema—Fluorouracil—head and neck cancer	0.00863	0.00951	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00845	0.00931	CcSEcCtD
Conivaptan—Constipation—Hydroxyurea—head and neck cancer	0.00837	0.00922	CcSEcCtD
Conivaptan—Pain—Hydroxyurea—head and neck cancer	0.00837	0.00922	CcSEcCtD
Conivaptan—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00807	0.00888	CcSEcCtD
Conivaptan—Pneumonia—Docetaxel—head and neck cancer	0.00802	0.00883	CcSEcCtD
Conivaptan—Anaemia—Fluorouracil—head and neck cancer	0.00798	0.00879	CcSEcCtD
Conivaptan—Infestation NOS—Docetaxel—head and neck cancer	0.00797	0.00878	CcSEcCtD
Conivaptan—Infestation—Docetaxel—head and neck cancer	0.00797	0.00878	CcSEcCtD
Conivaptan—Body temperature increased—Hydroxyurea—head and neck cancer	0.00774	0.00852	CcSEcCtD
Conivaptan—Diarrhoea—Vinblastine—head and neck cancer	0.00734	0.00809	CcSEcCtD
Conivaptan—Confusional state—Fluorouracil—head and neck cancer	0.0071	0.00782	CcSEcCtD
Conivaptan—Urinary tract disorder—Docetaxel—head and neck cancer	0.00707	0.00778	CcSEcCtD
Conivaptan—Oedema peripheral—Docetaxel—head and neck cancer	0.00705	0.00776	CcSEcCtD
Conivaptan—Urethral disorder—Docetaxel—head and neck cancer	0.00702	0.00773	CcSEcCtD
Conivaptan—Infection—Fluorouracil—head and neck cancer	0.007	0.00771	CcSEcCtD
Conivaptan—Nervous system disorder—Fluorouracil—head and neck cancer	0.00691	0.00761	CcSEcCtD
Conivaptan—Vomiting—Vinblastine—head and neck cancer	0.00682	0.00751	CcSEcCtD
Conivaptan—Headache—Vinblastine—head and neck cancer	0.00672	0.0074	CcSEcCtD
Conivaptan—Diarrhoea—Hydroxyurea—head and neck cancer	0.0067	0.00737	CcSEcCtD
Conivaptan—Cardiac disorder—Docetaxel—head and neck cancer	0.00664	0.00731	CcSEcCtD
Conivaptan—Hypotension—Fluorouracil—head and neck cancer	0.00658	0.00725	CcSEcCtD
Conivaptan—Angiopathy—Docetaxel—head and neck cancer	0.00649	0.00715	CcSEcCtD
Conivaptan—Mediastinal disorder—Docetaxel—head and neck cancer	0.00645	0.0071	CcSEcCtD
Conivaptan—Nausea—Vinblastine—head and neck cancer	0.00638	0.00702	CcSEcCtD
Conivaptan—Insomnia—Fluorouracil—head and neck cancer	0.00637	0.00702	CcSEcCtD
Conivaptan—Mental disorder—Docetaxel—head and neck cancer	0.00627	0.00691	CcSEcCtD
Conivaptan—Malnutrition—Docetaxel—head and neck cancer	0.00623	0.00686	CcSEcCtD
Conivaptan—Erythema—Docetaxel—head and neck cancer	0.00623	0.00686	CcSEcCtD
Conivaptan—Vomiting—Hydroxyurea—head and neck cancer	0.00622	0.00685	CcSEcCtD
Conivaptan—Headache—Hydroxyurea—head and neck cancer	0.00613	0.00675	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00608	0.0067	CcSEcCtD
Conivaptan—Pain—Fluorouracil—head and neck cancer	0.00603	0.00663	CcSEcCtD
Conivaptan—Nausea—Hydroxyurea—head and neck cancer	0.00581	0.0064	CcSEcCtD
Conivaptan—Feeling abnormal—Fluorouracil—head and neck cancer	0.00581	0.00639	CcSEcCtD
Conivaptan—Anaemia—Docetaxel—head and neck cancer	0.00576	0.00634	CcSEcCtD
Conivaptan—Body temperature increased—Fluorouracil—head and neck cancer	0.00557	0.00613	CcSEcCtD
Conivaptan—Hypertension—Docetaxel—head and neck cancer	0.00538	0.00592	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00527	0.0058	CcSEcCtD
Conivaptan—Dry mouth—Docetaxel—head and neck cancer	0.00519	0.00571	CcSEcCtD
Conivaptan—Confusional state—Docetaxel—head and neck cancer	0.00513	0.00565	CcSEcCtD
Conivaptan—Infection—Docetaxel—head and neck cancer	0.00505	0.00556	CcSEcCtD
Conivaptan—Nervous system disorder—Docetaxel—head and neck cancer	0.00499	0.00549	CcSEcCtD
Conivaptan—Pruritus—Fluorouracil—head and neck cancer	0.00498	0.00549	CcSEcCtD
Conivaptan—Skin disorder—Docetaxel—head and neck cancer	0.00494	0.00544	CcSEcCtD
Conivaptan—Diarrhoea—Fluorouracil—head and neck cancer	0.00482	0.00531	CcSEcCtD
Conivaptan—Hypotension—Docetaxel—head and neck cancer	0.00475	0.00523	CcSEcCtD
Conivaptan—Insomnia—Docetaxel—head and neck cancer	0.0046	0.00506	CcSEcCtD
Conivaptan—Vomiting—Fluorouracil—head and neck cancer	0.00448	0.00493	CcSEcCtD
Conivaptan—Headache—Fluorouracil—head and neck cancer	0.00441	0.00486	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00439	0.00483	CcSEcCtD
Conivaptan—Pain—Docetaxel—head and neck cancer	0.00435	0.00479	CcSEcCtD
Conivaptan—Constipation—Docetaxel—head and neck cancer	0.00435	0.00479	CcSEcCtD
Conivaptan—Feeling abnormal—Docetaxel—head and neck cancer	0.00419	0.00461	CcSEcCtD
Conivaptan—Nausea—Fluorouracil—head and neck cancer	0.00419	0.00461	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—KISS1—head and neck cancer	0.00416	0.0453	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00411	0.0448	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00408	0.0444	CbGpPWpGaD
Conivaptan—Body temperature increased—Docetaxel—head and neck cancer	0.00402	0.00443	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00372	0.0405	CbGpPWpGaD
Conivaptan—Pruritus—Docetaxel—head and neck cancer	0.0036	0.00396	CcSEcCtD
Conivaptan—AVPR2—Arf6 trafficking events—CDH1—head and neck cancer	0.00358	0.039	CbGpPWpGaD
Conivaptan—Diarrhoea—Docetaxel—head and neck cancer	0.00348	0.00383	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—GRP—head and neck cancer	0.00343	0.0373	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00338	0.0369	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00336	0.0366	CbGpPWpGaD
Conivaptan—Vomiting—Docetaxel—head and neck cancer	0.00323	0.00356	CcSEcCtD
Conivaptan—Headache—Docetaxel—head and neck cancer	0.00319	0.00351	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00307	0.0334	CbGpPWpGaD
Conivaptan—Nausea—Docetaxel—head and neck cancer	0.00302	0.00333	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00282	0.0307	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00276	0.03	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00274	0.0298	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00227	0.0247	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00225	0.0245	CbGpPWpGaD
Conivaptan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00219	0.0238	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—KISS1—head and neck cancer	0.0021	0.0229	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—KISS1—head and neck cancer	0.00208	0.0227	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00174	0.0189	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—GRP—head and neck cancer	0.00173	0.0188	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—GRP—head and neck cancer	0.00172	0.0187	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00148	0.0161	CbGpPWpGaD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00138	0.015	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.00133	0.0144	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00126	0.0137	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—KISS1—head and neck cancer	0.00119	0.0129	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—KISS1—head and neck cancer	0.00118	0.0128	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00115	0.0126	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00111	0.0121	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KISS1—head and neck cancer	0.00108	0.0117	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KISS1—head and neck cancer	0.00107	0.0116	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GRP—head and neck cancer	0.000977	0.0106	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GRP—head and neck cancer	0.00097	0.0106	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GRP—head and neck cancer	0.000887	0.00966	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GRP—head and neck cancer	0.000881	0.00959	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000657	0.00715	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KISS1—head and neck cancer	0.000636	0.00693	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KISS1—head and neck cancer	0.000632	0.00688	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000625	0.00681	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000625	0.0068	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000606	0.0066	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000593	0.00646	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000542	0.00591	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRP—head and neck cancer	0.000524	0.00571	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRP—head and neck cancer	0.00052	0.00567	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STAT6—head and neck cancer	0.000509	0.00554	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STAT6—head and neck cancer	0.000505	0.0055	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000502	0.00546	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000479	0.00522	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000473	0.00515	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—YAP1—head and neck cancer	0.00045	0.0049	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—YAP1—head and neck cancer	0.000447	0.00487	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000441	0.0048	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000435	0.00474	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000389	0.00423	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—head and neck cancer	0.00026	0.00283	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—head and neck cancer	0.000258	0.00281	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—head and neck cancer	0.000236	0.00257	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—head and neck cancer	0.000235	0.00256	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000218	0.00237	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000215	0.00234	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000206	0.00225	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000204	0.00222	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOTCH1—head and neck cancer	0.000203	0.00221	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOTCH1—head and neck cancer	0.000201	0.00219	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—MAPK3—head and neck cancer	0.00019	0.00207	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MAPK3—head and neck cancer	0.000189	0.00205	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UROD—head and neck cancer	0.000182	0.00198	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—MAPK1—head and neck cancer	0.000181	0.00197	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EGFR—head and neck cancer	0.000181	0.00197	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MAPK1—head and neck cancer	0.00018	0.00196	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EGFR—head and neck cancer	0.00018	0.00195	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000173	0.00188	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000172	0.00187	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CA—head and neck cancer	0.000157	0.00171	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CA—head and neck cancer	0.000156	0.0017	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HRAS—head and neck cancer	0.000145	0.00158	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HRAS—head and neck cancer	0.000144	0.00157	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKT1—head and neck cancer	0.000141	0.00154	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AKT1—head and neck cancer	0.00014	0.00153	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—head and neck cancer	0.00014	0.00152	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—head and neck cancer	0.000139	0.00151	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—head and neck cancer	0.000136	0.00148	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—head and neck cancer	0.000135	0.00147	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTEN—head and neck cancer	0.000131	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTEN—head and neck cancer	0.00013	0.00142	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKT1—head and neck cancer	0.000128	0.0014	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKT1—head and neck cancer	0.000127	0.00139	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VEGFA—head and neck cancer	0.000119	0.00129	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VEGFA—head and neck cancer	0.000118	0.00128	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STAT3—head and neck cancer	0.000118	0.00128	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STAT3—head and neck cancer	0.000117	0.00127	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK3—head and neck cancer	0.000112	0.00122	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK3—head and neck cancer	0.000111	0.00121	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK1—head and neck cancer	0.000107	0.00116	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EGFR—head and neck cancer	0.000107	0.00116	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK1—head and neck cancer	0.000106	0.00115	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EGFR—head and neck cancer	0.000106	0.00115	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CA—head and neck cancer	9.27e-05	0.00101	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CA—head and neck cancer	9.2e-05	0.001	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—head and neck cancer	8.97e-05	0.000977	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—head and neck cancer	8.9e-05	0.00097	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HRAS—head and neck cancer	8.58e-05	0.000934	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HRAS—head and neck cancer	8.52e-05	0.000927	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKT1—head and neck cancer	7.57e-05	0.000825	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NAT2—head and neck cancer	7.54e-05	0.000821	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKT1—head and neck cancer	7.52e-05	0.000819	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—DPYD—head and neck cancer	6.61e-05	0.00072	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—YAP1—head and neck cancer	6.27e-05	0.000683	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TYMS—head and neck cancer	3.77e-05	0.00041	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.72e-05	0.000406	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPX1—head and neck cancer	3.57e-05	0.000388	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.53e-05	0.000384	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.1e-05	0.000229	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTEN—head and neck cancer	1.83e-05	0.000199	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AKT1—head and neck cancer	1.06e-05	0.000115	CbGpPWpGaD
